Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950399 | 0.91 | PABPC1 (0.56) | ROCK2ROCK1NOTUMMEN1KMT2A | |
| SCHEMBL4952958 | 0.87 | ROCK2 (0.53) | ROCK2ROCK1NOTUMMEN1KMT2A | |
| SCHEMBL1245488 | 0.85 | HDAC1 (0.46) | ROCK2NOTUMTRPV1MEN1KMT2A | |
| SCHEMBL4952893 | 0.81 | NPC1 (0.52) | NOTUMMEN1KMT2APABPC1HDAC6 | |
| SCHEMBL1105174 | 0.80 | ROCK2 (0.61) | ROCK2ROCK1 | |
| SCHEMBL1245420 | 0.79 | RAB9A (0.56) | ROCK2ROCK1TRPV1MEN1KMT2A | |
| SCHEMBL4951758 | 0.79 | RAB9A (0.56) | ROCK2ROCK1TRPV1MEN1KMT2A | |
| SCHEMBL1245421 | 0.79 | RAB9A (0.56) | ROCK2ROCK1TRPV1MEN1KMT2A | |
| SCHEMBL5024166 | 0.79 | MCHR1 (0.51) | MEN1KMT2APABPC1HDAC6NPC1 | |
| SCHEMBL1244241 | 0.79 | HDAC1 (0.53) | ROCK2NOTUMMEN1KMT2APABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | ROCK2 2234/4885ROCK1 2365/4885NOTUM 1318/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | ROCK2 1383/4885ROCK1 1532/4885NOTUM 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.